SCHEMBL1531371

SCHEMBL1531371

N=C(N)[O]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guanidine SCHEMBL5102 0.78
Guanidine SCHEMBL9661571 0.78 ACHE (0.55)
Guanidine SCHEMBL1319550 0.78 ACHE (0.55)
Guanidine SCHEMBL14677179 0.78 ACHE (0.55)
Guanidine SCHEMBL27640020 0.75
Guanidine SCHEMBL28378215 0.75 ACHE (0.50)
Guanidine SCHEMBL5696251 0.75
Guanidine SCHEMBL8573951 0.75 LMNA (0.55)
Guanidine SCHEMBL7757618 0.75
Guanidine SCHEMBL165720 0.72 NOS2 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2480526-A1 CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PGI2 RECEPTOR AGONISTS Arena Pharmaceuticals, Inc. (US) 2012-08-01 EP claimed
WO-2011037613-A1 CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PGI2 RECEPTOR AGONISTS ARENA PHARMACEUTICALS, INC. (US) 2011-03-31 WO claimed
CN-219630243-U Drinking water deodorization and deodorization reaction tank 四川省国乐食品有限公司 2023-09-05 CN disclosed
CN-115894472-A Preparation method of high-purity azilsartan medoxomil potassium salt 仁合益康集团有限公司 2023-04-04 CN disclosed
US-20120225937-A1 CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PG12 RECEPTOR AGONISTS ARENA PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
EP-2480526-A1 CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PGI2 RECEPTOR AGONISTS Arena Pharmaceuticals, Inc. (US) 2012-08-01 EP disclosed
CN-102015647-A Process for production of compound having antagonistic activity on NPYY5 receptor, and useful crystal SHIONOGI & CO 2011-04-13 CN disclosed
WO-2011037613-A1 CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PGI2 RECEPTOR AGONISTS ARENA PHARMACEUTICALS, INC. (US) 2011-03-31 WO disclosed